Blueprint Medicines logo

BPMC - Blueprint Medicines Share Price

$72.8 -6.9  -8.7%

Last Trade - 4:55pm

Sector
Healthcare
Size
Large Cap
Market Cap £3.01bn
Enterprise Value £2.63bn
Revenue £12.3m
Position in Universe 1367th / 6416
Bullish
Bearish
Unlock BPMC Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

BPMC Revenue Unlock BPMC Revenue

Net Income

BPMC Net Income Unlock BPMC Revenue

Normalised EPS

BPMC Normalised EPS Unlock BPMC Revenue

PE Ratio Range

BPMC PE Ratio Range Unlock BPMC Revenue

Dividend Yield Range

BPMC Dividend Yield Range Unlock BPMC Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
BPMC EPS Forecasts Unlock BPMC Revenue
Profile Summary

Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. It focuses on crafting drug candidates that provide clinical responses to patients without adequate treatment options. It has developed a small molecule drug pipeline in cancer and a genetic disease. Its drug candidate, BLU-285, targets KIT, including Exon 17 mutations, and targets PDGFRa, including the D842V mutation. These mutations activate receptor tyrosine kinases that are drivers of cancer and proliferative disorders, including gastrointestinal stromal tumors (GIST), and systemic mastocytosis (SM). Its drug candidate BLU-554 targets FGFR4, a kinase that is activated in a defined subset of patients with hepatocellular carcinoma (HCC), the common type of liver cancer. It is engaged in developing BLU-667, a drug candidate that targets RET, a receptor tyrosine kinase that is activated by mutations or translocations.

Directors
Last Annual December 31st, 2018
Last Interim September 30th, 2019
Incorporated October 14, 2008
Public Since April 30, 2015
No. of Shareholders: 16
No. of Employees: 320
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market
Shares in Issue 49,202,122
Free Float (0.0%)
Eligible for
ISAs
SIPPs
BPMC Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for BPMC
Upcoming Events for BPMC
Monday 24th February, 2020 Estimate
Q4 2019 Blueprint Medicines Corp Earnings Release
Thursday 7th May, 2020 Estimate
Q1 2020 Blueprint Medicines Corp Earnings Release
Wednesday 17th June, 2020 Estimate
Blueprint Medicines Corp Annual Shareholders Meeting
Similar to BPMC
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.